Here are the Form 4 insider transactions from Scinai Immunotherapeutics Ltd. (SCNI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SCNI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCNI filings page.
GERMAIN MARK reported acquisition or exercise transactions in this Form 4 filing.
Scinai Immunotherapeutics director Mark Germain received a large equity award of 120,000,000 Ordinary Shares on June 16, 2026. The shares were granted at no cash cost as restricted share units and will vest in three equal annual installments, subject to his continued service. After this grant, he directly holds 120,000,000 Ordinary Shares, which are represented by American Depositary Shares, with each ADS currently corresponding to 4,000 Ordinary Shares.
Reichman Amir reported acquisition or exercise transactions in this Form 4 filing.
Scinai Immunotherapeutics Ltd. reported that Chief Executive Officer Amir Reichman received a grant of 400,000,000 Ordinary Shares on June 16, 2026 as a stock award. The shares were granted at a per-share price of $0.00 and are represented by restricted share units (RSUs).
The 400,000,000 Ordinary Shares vest in three equal annual installments after the grant date, subject to his continued service. After this award, Reichman directly owns 711,637,600 Ordinary Shares, including RSUs granted on January 25, 2024 and December 22, 2025, each with its own multi-year vesting schedule. Each American Depositary Share currently represents 4,000 Ordinary Shares.